Hormonal
GLP-1 receptor agonist therapy (semaglutide/tirzepatide) is increasingly driving referrals for post-weight-loss body contouring, with referral volumes growing faster than those from lifestyle modification or bariatric surgery.
If you are using GLP-1 medications like Ozempic or Mounjaro, be aware that rapid weight loss often leads to excess skin. You may need to consult a plastic surgeon for body contouring procedures. This is a common and expected outcome of significant weight loss via these medications.
Referral volumes increased across all pathways, with a positive but nonsignificant trend toward GLP-1–associated referrals (slope = +2.7 patients per interval; R² = 0.75; P = 0.14).
Why this rating
Retrospective observational study with small sample size (n=134) and non-significant p-values for trends.
Source
The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia
Armein Rahimpour et al. · Plastic & Reconstructive Surgery Global Open · 2026
DOI 10.1097/gox.0000000000007620
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →